Anti-human proBDNF monoclonal antibody, and uses thereof in pains
The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128 th amino acid in a specific recognition pro-BDNF precursor protein structural domain, a nucleic acid sequence for coding the antibody polypeptide, a carrier comprising the nucleic acid sequence, a host comprising the carrier, a pharmaceutical composition comprising the antibody, and the antibody in the preparation of drugs used for alleviating and/or suppressing chronic pains.
1. An antibody polypeptide that specifically recognizes the pro-BDNF pro-domain, including
1) a heavy chain variable region comprising the following amino acid sequences:
(a) CDR1 region of SEQ ID NO: 1,
(b) CDR2 region of SEQ ID NO: 2, and
(c) CDR3 region of SEQ ID NO: 3; and
2) a light chain variable region comprising the following amino acid sequences:
(d) CDR1 region of SEQ ID NO: 4,
(e) CDR2 region of SEQ ID NO: 5, and
(f) CDR3 region of SEQ ID NO: 6.
2. The antibody polypeptide of claim 1 , wherein the antibody polypeptide is a monoclonal antibody.
3. The antibody polypeptide of claim 2 , wherein the antibody polypeptide is selected from a humanized antibody polypeptide, a chimeric antibody polypeptide, an affinity maturated antibody polypeptide or one or more combinations thereof.
4. The antibody polypeptide of claim 1 , wherein the amino acid sequence of the heavy chain variable region is SEQ ID NO: 7.
5. The antibody polypeptide of claim 4 , wherein the amino acid sequence of the light chain variable region is SEQ ID NO: 8.
6. The antibody polypeptide of claim 1 , wherein the amino acid sequence of the heavy chain is SEQ ID NO: 9.
7. The antibody polypeptide of claim 6 , wherein the amino acid sequence of the light chain is SEQ ID NO: 10.
8. A method for mitigating and/or inhibiting pain selected from the group consisting of post-operative pain, acute inflammatory pain, chronic inflammatory pain, phantom limb pain, painful diabetic neuropathy, neuropathic pain, chronic lumbodorsalgia, chronic visceral pain, cancer pain, arthritis pain, craniofacial pain, trigeminal neuralgia, migraine, complex regional pain syndrome, and a combination thereof, the method comprising administering the antibody polypeptide of claim 1 .
9. A pharmaceutical composition comprising a therapeutically effective amount of the antibody polypeptide of claim 1 .
10. The pharmaceutical composition of claim 9 , which is administered by intravenous or intraperitoneal injection.
11. A monoclonal antibody polypeptide that specifically recognizes the pro-BDNF pro-domain, including
1) a heavy chain variable region comprising the following amino acid sequences:
(a) CDR1 region of SEQ ID NO: 1,
(b) CDR2 region of SEQ ID NO: 2, and
(c) CDR3 region of SEQ ID NO: 3; and
2) a light chain variable region comprising the following amino acid sequences:
(d) CDR1 region of SEQ ID NO: 4,
(e) CDR2 region of SEQ ID NO: 5, and
(f) CDR3 region of SEQ ID NO: 6;
wherein the antibody polypeptide comprises a conservative amino acid substitution within the CDR1, CDR2, or CDR3 region of the heavy chain variable region or the light chain variable region.
12. A nucleic acid encoding an antibody polypeptide that specifically recognizes the pro-BDNF pro-domain, including:
1) a heavy chain variable region comprising the following amino acid sequences:
(a) CDR1 region of SEQ ID NO: 1,
(b) CDR2 region of SEQ ID NO: 2, and
(c) CDR3 region of SEQ ID NO: 3; and
2) a light chain variable region comprising the following amino acid sequences:
(d) CDR1 region of SEQ ID NO: 4,
(e) CDR2 region of SEQ ID NO: 5, and
(f) CDR3 region of SEQ ID NO: 6.
13. The nucleic acid of claim 12 , comprising a nucleic acid having the sequence set forth in SEQ ID NO: 11 encoding the amino acid sequence of the heavy chain variable region of the antibody polypeptide and a nucleic acid having the sequence set forth in SEQ ID NO: 12 encoding the amino acid sequence of the light chain variable region of the antibody polypeptide.
14. The nucleic acid of claim 13 , comprising a nucleic acid having the sequence set forth in SEQ ID NO:13 encoding the amino acid sequence of the heavy chain of the antibody polypeptide and a nucleic acid having the sequence set forth in SEQ ID NO:14 encoding the amino acid sequence of the light chain of the antibody polypeptide.
15. A vector comprising a nucleic acid encoding an antibody polypeptide that specifically recognizes the pro-BDNF pro-domain, including:
1) a heavy chain variable region comprising the following amino acid sequences:
(a) CDR1 region of SEQ ID NO: 1,
(b) CDR2 region of SEQ ID NO: 2, and
(c) CDR3 region of SEQ ID NO: 3; and
2) a light chain variable region comprising the following amino acid sequences:
(d) CDR1 region of SEQ ID NO: 4,
(e) CDR2 region of SEQ ID NO: 5, and
(f) CDR3 region of SEQ ID NO: 6.
16. A host comprising a vector comprising a nucleic acid encoding an antibody polypeptide that specifically recognizes the pro-BDNF pro-domain, including:
1) a heavy chain variable region comprising the following amino acid sequences:
(a) CDR1 region of SEQ ID NO: 1,
(b) CDR2 region of SEQ ID NO: 2, and
(c) CDR3 region of SEQ ID NO: 3; and
2) a light chain variable region comprising the following amino acid sequences:
(d) CDR1 region of SEQ ID NO: 4,
(e) CDR2 region of SEQ ID NO: 5, and
(f) CDR3 region of SEQ ID NO: 6.